FAQ

Bay X 1005

Known as: Bay X1005, BAYX-1005, Bay-X1005 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2009
01219972009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
FLAP inhibitors for the treatment of inflammatory diseases.
Leukotrienes are lipid inflammatory mediators that are implicated in asthma, COPD, arthritis, cardiovascular disease and cancer… (More)
Is this relevant?
2005
2005
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
CONTEXT Myocardial infarction (MI) is the leading cause of death in the world. Variants in the 5-lipoxygenase-activating protein… (More)
Is this relevant?
2005
2005
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling…
BACKGROUND MMP-13 is one of the most important metalloproteases (MMP) involved in osteoarthritis. Licofelone, a novel dual… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2002
2002
Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
OBJECTIVE To compare the effect of licofelone, NS-398 (an inhibitor of cyclooxygenase 2 [COX-2]), and BayX-1005 (an inhibitor of… (More)
Is this relevant?
Review
1997
Review
1997
Biosynthesis inhibitors for leukotrienes in bronchial asthma.
This article reviews the literature on the effects of leukotrienes in asthma. In particular, the ability of recently developed… (More)
Is this relevant?